Assuntos
Acne Vulgar/tratamento farmacológico , Dermatologia/normas , Guias de Prática Clínica como Assunto , Acne Vulgar/diagnóstico , Acne Vulgar/microbiologia , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Gestão de Antimicrobianos/normas , Gestão de Antimicrobianos/tendências , Peróxido de Benzoíla/uso terapêutico , Anticoncepcionais Orais/uso terapêutico , Dermatologia/métodos , Dermatologia/tendências , Esquema de Medicação , Farmacorresistência Bacteriana , Feminino , Humanos , Isotretinoína/uso terapêutico , Masculino , Índice de Gravidade de Doença , Globulina de Ligação a Hormônio Sexual , Espironolactona/uso terapêutico , Fatores de TempoRESUMO
INTRODUCTION: Routine use of doxycycline (DC) 100 mg for the treatment of moderate to severe acne may be associated with gastrointestinal adverse events (AEs), thus potentially impacting patient adherence, and antibiotic resistance. This study evaluated the safety and efficacy of subantimicrobial, modified-release (MR) DC 40 mg compared to DC 100 mg and to placebo for the treatment of inflammatory lesions in moderate and severe acne. METHODS: 662 subjects aged 12 years or older with moderate to severe acne received subantimicrobial, MR-DC 40 mg tablets, DC 100 mg capsules, or placebo once daily for 16 weeks. RESULTS: MR-DC 40 mg was superior to placebo in the mean reduction of the number of inflammatory lesions, median percent reduction in inflammatory and total lesions, and success rate. MR-DC 40 mg was also comparable to DC 100 mg in the reduction of the number of inflammatory lesions, and percent reduction of total lesions. Incidence of drug-related AEs for MR-DC 40 mg was similar to placebo and was markedly smaller compared to DC 100 mg. DISCUSSION: MR-DC 40 mg demonstrated comparable efficacy and superior safety to DC 100 mg in the treatment of moderate to severe inflammatory acne.
Assuntos
Acne Vulgar/tratamento farmacológico , Anti-Infecciosos/uso terapêutico , Doxiciclina/uso terapêutico , Adolescente , Adulto , Idoso , Anti-Infecciosos/administração & dosagem , Anti-Infecciosos/efeitos adversos , Criança , Preparações de Ação Retardada , Método Duplo-Cego , Doxiciclina/administração & dosagem , Doxiciclina/efeitos adversos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento , Adulto JovemRESUMO
Despite their beneficial effects on the treatment of acne vulgaris, topical and oral retinoids may cause severe local irritation (retinoid dermatitis) due to their mechanism of action, thereby jeopardizing patient adherence, and thus compromising treatment efficacy. Alleviating dryness and improving skin comfort by using a moisturizer concomitantly to retinoids could enhance efficacy. In the present study, 30 subjects receiving either oral isotretinoin for at least 2 months or topical tretinoin for at least one month applied a moisturizing cream (Cetaphil Moisturizing Cream) twice daily for 15 days on one half of the face while the other side remained untreated. Clinical assessments, confirmed by biophysical measurements, showed that the moisturizer provided a significant improvement in skin dryness, roughness, and desquamation. Skin properties and skin discomfort were also greatly improved and subjects were very satisfied with the product. Retinoid-induced skin irritation can be relieved by the regular use of a gentle moisturizing cream as an adjunctive treatment.
